EDWARDS LIFESCIENCES CORPORATION Edwards Lifesciences Corporation Stock Swiss Exchange
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.6 CHF | -1.45% |
|
-.--% | -.--% |
| May. 23 | Some of the biggest splits in Corporate America | RE |
| May. 22 | Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 | MT |
| Sales 2024 * | 6.56B 5.92B | Sales 2025 * | 7.2B 6.5B | Capitalization | 52.36B 47.22B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.61B 1.45B | Net income 2025 * | 1.86B 1.68B | EV / Sales 2024 * | 7.72 x |
| Net cash position 2024 * | 1.7B 1.53B | Net cash position 2025 * | 2.84B 2.56B | EV / Sales 2025 * | 6.87 x |
| P/E ratio 2024 * |
32.9
x | P/E ratio 2025 * |
28.3
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.59% |
More Fundamentals
* Assessed data
More news
Latest transcript on Edwards Lifesciences Corporation
More recommendations
More press releases
More news
5 years
47.58
64.24
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 14-12-31 | |
Scott Ullem
DFI | Director of Finance/CFO | 57 | 13-12-31 |
Todd Brinton
CTO | Chief Tech/Sci/R&D Officer | - | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leslie Heisz
BRD | Director/Board Member | 63 | 16-07-04 |
| Chairman | 67 | 14-11-12 | |
Steven Loranger
BRD | Director/Board Member | 72 | 16-03-15 |
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-06-04
- William Blair Growth Stock Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
86.89
USD
Average target price
96.55
USD
Spread / Average Target
+11.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.29% | 64.59B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.6B | |
| +19.95% | 30.31B |
- Stock Market
- Equities
- EW Stock
- EW Stock
